Axovant Licenses Investigational Gene Therapy for Parkinson’s Disease from Oxford BioMedica and Announces Key Leadership Team Addition Biotech Investing
argenx receives feedback from FDA in end-of-phase 2 meeting for efgartigimod in myasthenia gravis Biotech Investing
Takeda and TiGenix Announce Results of First Acceptance Period for the Voluntary and Conditional Public Takeover Bid of TiGenix Pharmaceutical Investing
VANC Bolsters Hema-Fer Market Presence with Amazon Canada Store Launch and Advertising Approvals Pharmaceutical Investing
BioCryst Issues Letter to Stockholders Reiterating Upside Potential of Value-Enhancing Merger with Idera Pharmaceutical Investing
AtriCure and Baheal Group Establish Partnership and China Distribution Agreement Pharmaceutical Investing
Verastem Oncology and Yakult Honsha Sign Exclusive License Agreement for the Development and Commercialization of Duvelisib in Japan Pharmaceutical Investing
Chugai’s HEMLIBRA Receives Priority Review Status from U.S. FDA for Hemophilia A Without Inhibitors Pharmaceutical Investing
